CSF Biomarkers and Liquid Biopsy for Glioblastoma: What Your Spinal Fluid Can Reveal About Tumor Activity Between Scans

The Gap Between Scans

Most glioblastoma patients and families describe the weeks between MRI appointments as some of the hardest in the entire treatment experience. The scan answers some questions. But between those appointments, there is no standard way to know what the tumor is doing at the molecular level — whether treatment is working, whether something is shifting before it becomes visible on imaging, or whether the tumor is changing under treatment pressure.

That gap is exactly where cerebrospinal fluid (CSF) biomarker analysis and liquid biopsy research are gaining serious scientific attention. The fluid surrounding your brain and spinal cord already carries fragments of tumor DNA, proteins, and other molecular signals shed directly by the tumor. Researchers are advancing methods to read those signals and what they may reveal when standard imaging cannot.

This article explains what CSF liquid biopsy is, what current evidence supports, where its real limits lie, and what this approach means for patients and families working to understand glioblastoma biology between scans.

What Cerebrospinal Fluid Actually Is

Cerebrospinal fluid is the clear liquid that flows through and around the brain and spinal cord. The body produces approximately 500 milliliters per day, maintaining a constant volume of roughly 150 milliliters at any given time. CSF cushions the central nervous system, carries nutrients, and removes cellular waste.

Because CSF touches brain tissue directly, including tumor tissue, it collects materials that the tumor continuously sheds. This includes fragments of tumor DNA, small membrane-enclosed particles called extracellular vesicles, microRNA molecules, and proteins associated with tumor metabolism and growth. This direct contact is why CSF is considered a better source of glioblastoma signals than blood in most research settings.

CSF is typically collected through a lumbar puncture, a spinal tap in which a fine needle goes into the lower spine under local pain relief. In patients who already have an Ommaya reservoir or ventriculoperitoneal shunt in place from earlier surgery, repeated sampling may be possible through those existing devices.

Why Every Glioblastoma Behaves Differently

Glioblastoma is not a single disease. Two patients with the same WHO Grade IV diagnosis and similar imaging findings may have tumors with entirely different molecular makeup. One tumor may have EGFR amplification. Another may carry PTEN loss, CDKN2A deletion, or a TERT promoter mutation that changes how it responds under treatment. These differences are biological, and they influence everything from which treatments work to how fast the tumor grows over time.

This molecular diversity also shapes what individual tumors shed into surrounding fluid. The type and quantity of biomarkers in any patient's CSF will show that specific tumor's current activity, not a generic GBM average. This is why CSF analysis must always be read with a patient's full molecular profile rather than as a standalone finding. The biology is individual, and the information derived from it needs to be treated that way.

Why CSF Carries More Tumor Signal Than Blood

Glioblastoma tumors exist behind the blood-brain barrier, a tightly controlled cellular network that controls what gets through between brain tissue and the peripheral bloodstream. This barrier is one reason why blood-based liquid biopsy doesn't work as well for GBM. Research has found that circulating tumor DNA (ctDNA) is found in blood plasma in roughly 16% of glioblastoma patients, compared with around 82% of patients when CSF is sampled directly, according to a detailed review of CSF biomarkers for glioma diagnosis and monitoring published in the International Journal of Molecular Sciences.

CSF bypasses this limitation because it is already on the brain side of the barrier. Tumor cells shed genetic fragments and molecular material directly into the fluid that surrounds them. Researchers describe CSF as the richest biomarker source currently accessible for central nervous system tumors, one that may show molecular changes weeks before they appear on standard MRI.

For patients already researching blood-based monitoring approaches, our article on circulating tumor DNA and liquid biopsy monitoring from blood tests explains why blood-based ctDNA testing works differently from CSF-based analysis and how the two approaches may eventually work together in a more complete monitoring plan.

The Biomarkers CSF Can Carry

Several categories of tumor-related material have been identified in the CSF of glioblastoma patients. Research is ongoing to establish the clinical role of each:

• Circulating tumor DNA (ctDNA): Fragments of tumor DNA shed from actively dividing or dying cells. These can carry tumor-specific mutations including EGFR amplification, TERT promoter alterations, CDKN2A deletions, and MGMT methylation changes that show the molecular state of the tumor at the time of sampling. A 2025 study on longitudinal CSF cell-free DNA monitoring in glioma patients, published in Clinical Cancer Research, found that serial CSF sampling was possible and that changes in molecular variant profiles matched clinical outcomes over the course of treatment.
• MicroRNAs (miRNAs): Small regulatory RNA molecules that show cellular stress and tumor activity. A specific CSF miRNA signature studied in glioblastoma patients showed sensitivity of 67% and specificity of 80% in cisternal CSF samples. Extracellular vesicle-derived miRNA panels from CSF have shown specificity as high as 95% in early exploratory studies.
• Extracellular vesicles (EVs) and exosomes: Membrane-enclosed particles released by tumor cells that carry proteins, RNA, and DNA material which may show the tumor's current genetic state and activity level.
• Tumor-derived proteins: Proteins including glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) can be higher in the CSF of patients with active brain tumor disease and may signal neurological stress and tumor burden.

A comprehensive 2024 review of circulating liquid biopsy biomarkers in glioblastoma notes that no single CSF biomarker is ready for routine clinical use on its own, but combining ctDNA detection with protein and EV-derived markers could improve both diagnostic accuracy and monitoring reliability over time.

The Pseudoprogression Problem — When MRI Cannot Distinguish

A recognized clinical challenge in glioblastoma management is pseudoprogression. After chemoradiation, typically the Stupp protocol combining temozolomide with concurrent radiotherapy, an MRI scan might show new tumor growth or increasing contrast enhancement. In many of these cases, the imaging change is treatment-related tissue inflammation rather than real tumor growth. This is pseudoprogression.

Standard MRI cannot reliably tell the difference between pseudoprogression and true tumor progression in a significant number of patients. Advanced imaging techniques such as MR spectroscopy and perfusion imaging provide additional data but aren't perfect. This ambiguity has real clinical consequences. Mistaking pseudoprogression for true recurrence might cause you to stop a treatment that is actually working. Missing real early tumor growth means you wait too long to change strategy.

This is where CSF biomarkers may add useful information. Research specifically examining liquid biopsy strategies for distinguishing true progression from pseudoprogression and radiation necrosis in glioblastoma found that rising ctDNA levels in CSF matched histologically confirmed true tumor progression in cases where imaging wasn't clear. The absence of rising ctDNA matched better with pseudoprogression confirmed by later testing. This does not mean CSF testing replaces tissue biopsy or advanced imaging. It could add useful information that helps you make better choices at hard moments in glioblastoma care.

Common Mistakes Families Make When Monitoring GBM

Several patterns appear consistently among families dealing with glioblastoma monitoring. Understanding them may help avoid costly delays:

• Assuming MRI is the only monitoring option: Families are rarely told that blood or fluid tests exist or are being studied. Most consultations focus on scan results. What the tumor is doing between scans rarely comes up unless patients specifically ask.
• Not retaining all molecular reports and imaging files: Pathology reports, molecular testing results, surgical notes, and DICOM imaging files are important. Many families discover too late that earlier reports are no longer accessible through their institution's portal.
• Treating standard molecular profiling as complete: Routine MGMT and IDH testing isn't a full molecular profile. Broader genomic analysis, including whole exome sequencing and RNA sequencing, might find weak spots not caught in standard reporting. A tumor that looks well-characterized on a standard report may have treatment targets that were never tested for.
• Not seeking specialist review of confusing scan results: When an MRI is described as showing possible progression, the question of whether this is true recurrence or pseudoprogression should be discussed with a specialist in brain tumor molecular biology, not only the local treating team.

How CSF Intelligence Connects to Precision Oncology Strategy

Understanding a glioblastoma's molecular behavior is not a one-time event at diagnosis. It is a dynamic, ongoing process. Tumors evolve under treatment pressure. Mutations present at surgery may shift. New weak spots may appear when the tumor comes back that weren't in the original tissue sample. Serial CSF biomarker analysis, particularly tracking ctDNA and molecular alterations across multiple time points, could track that evolution without requiring repeat surgery.

When interpreted with molecular profiling data from the original resection, including whole exome sequencing, MGMT methylation status, EGFR amplification, TERT promoter mutation, and drug sensitivity analysis, CSF findings can add important information to your overall tumor picture. This combined approach, using tissue-based molecular data with fluid-based monitoring across your treatment timeline, shows where precision tumor medicine is headed.

For patients still working to understand their initial molecular report, our guide to interpreting your glioblastoma molecular report explains how genetic mutations, pathway alterations, and biomarker findings affect treatment choices and why understanding your tumor at diagnosis is the base for any monitoring you do later.

What International Patients Are Doing

Patients and caregivers in London, Manchester, New York, Sydney, Toronto, Dubai, Berlin, and Melbourne are increasingly getting expert review of their tumor biology that goes beyond what standard local reporting provides. This reflects the complexity of glioblastoma and the reality that interpreting CSF biomarker data with whole exome sequencing results, treatment history, and drug sensitivity profiles requires expertise that most cancer teams can't provide in one appointment.

Where the expert is located doesn't matter. Reports can be reviewed remotely. MRI scans can be assessed digitally from DICOM files. Molecular testing results can be interpreted by specialists without the patient traveling anywhere. Many families begin with a virtual consultation and a structured document review before deciding on next steps. What matters is how well they understand your tumor and what questions they help you ask your team.

Major medical centers and researchers are investing in this field. Clinical trials examining CSF biomarker monitoring as part of glioblastoma management are registered on ClinicalTrials.gov, showing that specialist centers are serious about tracking how the tumor changes.

What Reports Should You Gather Before Seeking an Expert Review?

Whether or not CSF biomarker analysis is part of your current situation, gathering the right documents before a precision-oncology consultation makes the process more useful and more targeted from the first conversation:

• Pathology Report: Confirming tumor type, WHO grade, and classification.
• Histopathology Report: Detailed cellular analysis including tumor density and cell patterns relevant to treatment behavior.
• MRI Brain Reports: All scan reports from diagnosis, post-surgery, and every follow-up timepoint. DICOM image files if you can get them.
• Surgical Notes: Extent of resection, surgical approach, and any intraoperative findings including fluorescence-guided or mapping data.
• Molecular Testing Results: MGMT methylation, IDH mutation status, EGFR amplification, TERT promoter mutation, CDKN2A status, and any broader genomic panel data including whole exome sequencing results.
• Current Treatment Plan: Active therapies, including any clinical trial participation and the specific protocol being followed.
• Previous Treatment History: All prior radiation (with dose and fractionation details), chemotherapy cycles and cumulative dosing, and any surgical interventions.

A complete checklist of what you need to gather, including things families often forget, is available in our detailed guide to preparing for your tumor intelligence review.

Questions Worth Raising With Your Oncology Team

• Is CSF liquid biopsy or serial ctDNA monitoring available through this center or a specialist laboratory we could be referred to?
• If the next MRI shows possible progression, would CSF biomarker data be considered as part of the decision process before changing treatment?
• Has my tumor been fully characterized beyond MGMT and IDH, including EGFR, TERT, CDKN2A, and PTEN status?
• Are there clinical trials at this center or at a specialist referral center that incorporate CSF monitoring as part of the protocol?
• If a lumbar puncture is indicated for any clinical reason, can CSF be simultaneously stored for research biomarker analysis?

Next Steps

Every glioblastoma is biologically distinct. The molecular profile of your tumor and the signals it may currently be generating in cerebrospinal fluid might show things your current reports don't. Learning more about your tumor may open questions worth discussing with your treating team and could point to new treatment options that would otherwise remain unexplored.

If you or someone you care for has been diagnosed with glioblastoma, whether newly diagnosed or at recurrence, gather your pathology reports, MRI scans, surgical notes, and all molecular testing results. A precision-oncology review can assess the available data, find important information, and help you understand the questions most worth raising with your treating physicians.

Understanding your tumor's biology is something you can actively do in the weeks between scans.

When to Talk to Your Doctor

Raise CSF biomarker testing with your neuro-oncologist if your next MRI raises questions about pseudoprogression versus true tumor regrowth, if your tumor's initial testing wasn't complete and broader characterization could help choose your next treatment, or if you are researching clinical trials that incorporate liquid biopsy monitoring as part of eligibility or response criteria.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.